NCT02824224View on ClinicalTrials.gov

Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 6, 2016

Primary Completion Date

January 8, 2018

Study Completion Date

January 8, 2018

Conditions

MenorrhagiaMetrorrhagiaMedicated Intrauterine Devices

Interventions

DRUG

Tamoxifen

10mg PO (by mouth) twice daily for 7 days starting on day 21 after IUD insertion for one course

DRUG

Placebo (for Tamoxifen)

Sugar pill manufactured to mimic the tamoxifen 10mg tablet

Trial Locations (1)

97239

OHSU Center For Women's Health, Portland

All Listed Sponsors

lead

Oregon Health and Science University

OTHER

NCT02824224 - Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS) | Biotech Hunter | Biotech Hunter